



Excess mortality in the United States during the first three months of the COVID-19 pandemic

R. Rivera¹ , J. E. Rosenbaum²  and W. Quispe¹

¹College of Business, University of Puerto Rico at Mayagüez, Mayagüez, Puerto Rico and ²Department of Epidemiology and Biostatistics, School of Public Health, SUNY Downstate Health Sciences University, Brooklyn, NY, USA

Original Paper

Cite this article: Rivera R, Rosenbaum JE, Quispe W (2020). Excess mortality in the United States during the first three months of the COVID-19 pandemic. *Epidemiology and Infection* **148**, e264, 1–9. <https://doi.org/10.1017/S0950268820002617>

Received: 19 June 2020
Revised: 21 October 2020
Accepted: 27 October 2020

Key words:

COVID-19; epidemiology; excess deaths; infectious disease; natural disasters

CI: confidence intervals; COVID-19: Coronavirus Disease 2019; ED: emergency department; ILI: Influenza-like Illness; MSS: Mortality Surveillance System; NCHS: National Center for Health Statistics; NNSP: National Syndromic Surveillance Program; NYC: New York City; PCR: Polymerase chain reaction; SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2; US: United States

Author for correspondence:

R. Rivera, E-mail: roberto.rivera30@upr.edu

Abstract

Deaths are frequently under-estimated during emergencies, times when accurate mortality estimates are crucial for emergency response. This study estimates excess all-cause, pneumonia and influenza mortality during the coronavirus disease 2019 (COVID-19) pandemic using the 11 September 2020 release of weekly mortality data from the United States (U.S.) Mortality Surveillance System (MSS) from 27 September 2015 to 9 May 2020, using semiparametric and conventional time-series models in 13 states with high reported COVID-19 deaths and apparently complete mortality data: California, Colorado, Connecticut, Florida, Illinois, Indiana, Louisiana, Massachusetts, Michigan, New Jersey, New York, Pennsylvania and Washington. We estimated greater excess mortality than official COVID-19 mortality in the U.S. (excess mortality 95% confidence interval (CI) 100 013–127 501 vs. 78 834 COVID-19 deaths) and 9 states: California (excess mortality 95% CI 3338–6344) vs. 2849 COVID-19 deaths); Connecticut (excess mortality 95% CI 3095–3952) vs. 2932 COVID-19 deaths); Illinois (95% CI 4646–6111) vs. 3525 COVID-19 deaths); Louisiana (excess mortality 95% CI 2341–3183 vs. 2267 COVID-19 deaths); Massachusetts (95% CI 5562–7201 vs. 5050 COVID-19 deaths); New Jersey (95% CI 13 170–16 058 vs. 10 465 COVID-19 deaths); New York (95% CI 32 538–39 960 vs. 26 584 COVID-19 deaths); and Pennsylvania (95% CI 5125–6560 vs. 3793 COVID-19 deaths). Conventional model results were consistent with semiparametric results but less precise. Significant excess pneumonia deaths were also found for all locations and we estimated hundreds of excess influenza deaths in New York. We find that official COVID-19 mortality substantially understates actual mortality, excess deaths cannot be explained entirely by official COVID-19 death counts. Mortality reporting lags appeared to worsen during the pandemic, when timeliness in surveillance systems was most crucial for improving pandemic response.

Introduction

The number of Coronavirus Disease 2019 (COVID-19) deaths may be under-reported, and COVID-19 may be indirectly responsible for additional deaths. The Centers for Disease Control and Prevention issues guidelines to determine cause of deaths, but underestimating the death toll of natural disasters, heatwaves, influenza and other emergencies is common. In some cases, the underestimates can be extreme: chikungunya was officially associated with only 31 deaths during a 2014–2015 epidemic in Puerto Rico, but time-series analysis estimated excess mortality of 1310 deaths [1]. Hurricane Maria's mortality was officially only 64 deaths, but a 95% confidence interval for estimated excess mortality was between 1069 and 1568 [2]. Deaths directly due to the COVID-19 pandemic may be underestimated due to under-diagnosis [3], insufficient postmortem severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) tests, not seeking healthcare [4] and ascertainment bias. Deaths indirectly due to an emergency are also common, due to an overloaded health system [5] or lack of healthcare access for routine care: during the 2014 West Africa Ebola epidemic, lack of routine care for malaria, HIV/AIDS and tuberculosis led to an estimated 10 600 additional deaths in the area [6]. Health emergencies may also lead to indirect deaths from economic, social and emotional stress [7] and crowded emergency departments [8].

In this study, we estimate excess all-cause, pneumonia and influenza mortality during the COVID-19 pandemic, which includes deaths both directly and indirectly related to COVID-19. Directly related COVID-19 deaths include deaths in patients who have undetected SARS-CoV-2 due to false-negative tests [9] not seeking healthcare [4], or being turned away from the emergency department due to emergency department crowding [8]. Testing and forensic staff shortfalls lead to lack of postmortem testing. Indirect deaths are deaths not due to COVID-19 and may include deaths among patients due to emergency department crowding [8]; avoidance of hospitals due to fear of the virus; or avoidance of healthcare due to the accompanying economic recession, such as loss of employment or income, or loss of health insurance coverage [10].

© The Author(s), 2020. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Methods

Data and measures

Weekly all-cause, pneumonia and influenza mortality for each state from 27 September 2015 (week 40) to 9 May 2020 (week 19) were obtained from the National Center for Health Statistics (NCHS) Mortality Surveillance System (MSS) data release on 11 September 2020. The MSS presents weekly death certificate counts, without regard to whether deaths were classified as related to COVID-19. Based on ICD-10 multiple cause of death codes, pneumonia and influenza deaths were also made available. The timeliness in death certificate reporting varies by region, state and cause of death [11]. We use pneumonia and influenza mortalities because COVID-19 deaths could be misclassified as pneumonia or influenza. The NCHS divides New York State into two jurisdictions: New York City (NYC) and non-NYC New York State, and we leave them separate for plots and combine them for statistical models.

We identified 13 jurisdictions within this data that had high numbers of reported COVID-19 deaths through 9 May 2020. The states were: California, Colorado, Connecticut, Florida, Illinois, Indiana, Louisiana, Massachusetts, Michigan, New Jersey, New York, Pennsylvania and Washington.

Population estimates were from Vintage 2019 Census yearly estimates for 1 July of each year 2010–2019, which were used to obtain weekly population estimates [12].

We obtained COVID-19 mortality counts through 9 May 2020 from the COVID-19 Tracking Project, the New York Times and the Centers for Disease Control Provisional Deaths. Usually, CDC provisional counts were the highest estimate [13–15]. These three mortality counts differ, so we used the higher number in all cases to be conservative with respect to the null hypothesis that excess mortality can be explained entirely by official COVID-19 death counts: that is, the lower bound of excess mortality is below official COVID-19 deaths. To assess whether the COVID-19 pandemic was associated with reduced emergency department (ED) utilisation not for COVID-19, we identified 3 of the United States top 5 causes of death that present with acute symptoms that require immediate treatment, for which the choice not to seek healthcare may result in death: heart disease, chronic lower respiratory diseases and cerebrovascular disease. Among the 59 National Syndromic Surveillance Program (NSSP) jurisdictions, we were only able to obtain daily ED visits in New York City for asthma symptoms. We obtained daily counts of asthma ED visits, age group (5–17, 18–64, 65+), borough and date from the New York City Department of Health and Mental Hygiene's EpiQuery website from 1 January 2016 to 9 May 2020. This study is an analysis of publicly available data in broad categories such that individuals cannot be identified, so it is not human subjects research and is exempt from requiring human subjects board review.

Statistical analysis

We construct two models to capture the temporal behaviour of death certificate data to estimate excess mortality during the COVID-19 pandemic: a semiparametric model and a conventional model estimating the difference in current death totals starting from the beginning of the pandemic and the projected deaths under normal conditions [16]. In what follows, we briefly describe each excess deaths model. See [Appendix](#) for further details.

Semiparametric model

We use a semiparametric model to capture the temporal behaviour of mortality while measuring how the pandemic alters the 'normal' mortality pattern. This model was successfully deployed to estimate excess deaths due to Hurricane Maria in Puerto Rico [2].

Specifically, we define a general additive model with the following covariates: the natural logarithm of population as an offset, a smooth function of week of the year, year category and a binary variable coded as 1 for dates on or after the start of the pandemic and 0 prior to the starting point; its coefficient presents the possibility that the mean death rate has changed after the start of the pandemic at some location. The week of the year is modelled non-parametrically with a penalised cyclic cubic regression spline function to capture seasonal mortality variations [15]. Preliminary analysis indicated overdispersion, so we used a quasi-Poisson model to estimate the dispersion parameter [17]. We estimated coefficients by a penalised likelihood maximisation approach, where the smoothing penalty parameters are determined by restricted maximum likelihood. The residuals of the fitted model did not present remaining temporal dependence.

To estimate cumulative excess deaths, we sum the coefficients of the indicator for the start of the pandemic. Approximate simulations from the Bayesian posterior density are performed to obtain 95% credibility intervals, which we refer to as confidence intervals throughout.

For each state, we determine excess deaths due to the COVID-19 pandemic from a starting point through 9 May, the date of the most recent complete mortality data at the time of our analysis. The starting point was the date after the most recent inflection point in all-cause mortality, suggesting the onset of the COVID-19 pandemic, chosen to balance concerns of deaths prior to the official first cases and the sensitivity of the model to detect small excess mortality in the limited available data, exacerbated by the provisional counts being lower than actual deaths: 29 February for Washington state, 28 March for Florida, Indiana and Massachusetts and 21 March for the remaining 9 states and for the United States as a whole. This semiparametric model can incorporate population displacement [2], but we are not aware of significant displacement during the pandemic. Specifically, New York City was uniquely affected during this first wave of infections, with a public perception of widespread community infections acquired in a crowded metropolitan area that relies on public transportation. Analysis of data from smart phones finds that about 400 000 New York City residents, 5% of the population of New York City, left the city between 1 March and 1 May 2020, and departures were characterised by substantial wealth and race disparities [18]. NYC residents dispersed to locations around the country, with most locations receiving less than 4000 people from this total, a negligible addition (<1%) to the state populations; locations receiving more than 4000 people included non-NYC New York State, Pennsylvania, New Jersey, Connecticut and Florida [18].

A conventional excess deaths analysis

We also estimate excess mortality using a conventional excess mortality method: we fit a quasi-Poisson semiparametric model as above until 1 February 2020. The deaths from 8 February 2020 forward should follow a Poisson distribution with some expected rate; the maximum-likelihood estimator of such rate is the mean weekly deaths during this period. Weekly deaths are




Fig. 1. Provisional weekly all-cause, pneumonia and influenza mortality counts for the United States from weekly data releases 10 April–12 June 2020.

approximately normally distributed with a variance that accounts for overdispersion according to the scale parameter in the fitted model. From this distribution, we simulate 10 000 weekly deaths and subtract the results from the posterior distributions of the fitted results. The 95% confidence interval is the range between the 2.5% and 97.5% percentiles of all excess deaths.

The models were fit using version 1.8-28 of the *mgcv* package in R 4.0.2 [19, 20]. All code and data have been made publicly available (<https://github.com/bakuninpr/COVID-Excess-Deaths-US>). The statistical analyses were conducted between April and September 2020.

Assessing reduction in emergency department utilisation

To evaluate whether there was a reduction in emergency department visits during the period from 21 March to 9 May, we fit a quasi-Poisson regression model for daily number of asthma-related emergency department visits in New York City syndromic surveillance data, controlling for borough, age group and date, with a binary variable for date after 21 March 2020; this model estimated a dispersion parameter of 1.95.

Results

Provisional death counts increase with each data release, especially for recent weeks. The variation on reporting timeliness by state hinders excess death assessment for the United States. Figure 1 shows all-cause mortality counts for successive data releases. Successive releases of weekly mortality counts 'blanket' each previous release, with gaps between the lines representing differences in each data release. During the pandemic, large gaps between successive data releases during periods of higher deaths suggests that mortality reporting lags are larger during periods of elevated deaths: the discrepancy between the number of all-cause deaths for the last week of the 1 April data release and the corresponding entry of the 12 June release is 18%. In contrast, the discrepancy between the number of all-cause deaths for the last week of the 29 May data release and the corresponding entry of the 12 June

release is 75%. The effects on mortality of the COVID-19 pandemic is clearly seen in Figure 2, although the effect has substantial local variation. All states have excess pneumonia mortality (Fig. 3), and New York City shows hundreds of excess influenza deaths over several weeks (Fig. 4).

In the United States, we observe greater all-cause and pneumonia deaths (Fig. 5). Using the semiparametric model, between 21 March 2020 and 9 May 2020 we are 95% confident that all-cause excess deaths in the United States were between 100 013 and 127 501, compared with 78 834 reported COVID-19 deaths, which is at least 21 179 more deaths than official COVID-19 deaths for the same time period. Pneumonia excess deaths were between 40 066 and 47 391. Using the conventional method, we found a 95% confidence interval of 106 940 and 143 478 for all-cause excess deaths in the United States, and 41 613 and 47 841 for pneumonia deaths.

For each state Table 1 presents 95% confidence intervals for all-cause, pneumonia and influenza excess deaths. We estimated greater excess mortality than COVID-19 deaths in 10 of 13 states: Florida, Indiana and Washington present significant all-cause excess mortality but there was no evidence of them exceeding official COVID-19 death counts. However, relative to expected numbers of pneumonia and influenza deaths, we observe excess pneumonia deaths in all states studied, and excess influenza deaths in New York while excess influenza deaths in New Jersey are less clear (Table 1). We evaluated influenza mortality in the District of Columbia, the other urban-only area, but influenza deaths were not higher than usual (not shown), in contrast to New York City.

With the conventional model, we estimate more excess all-cause deaths than reported COVID-19 cases except in Colorado, Florida, Indiana and Washington (Table 1); and once more excess pneumonia deaths are observed for all states. These results are also consistent with the excess mortality results for the earlier data release covering through 9 May 2020 (not shown).

The results of the semiparametric and conventional models are generally compatible. But since our conventional model also reflects random fluctuations in mortality, prediction intervals




Fig. 2. Weekly all-cause mortality grouped by year and state starting on week 40 of 2015 until 9 May 2020.




Fig. 3. Weekly pneumonia mortality grouped by year and state starting on week 40 of 2015 until 9 May 2020.

are obtained, which naturally present larger variation than confidence intervals. Treating the deaths as fixed [16] would lead to intervals that are misleadingly short on width. The larger uncertainty in the conventional model makes it harder to interpret excess deaths.

Using the quasi-Poisson model with the outcome daily emergency department visits for asthma syndrome in NYC, we found that during this period, asthma visits were 64% lower than expected, a substantial drop (IRR = 0.36, 95% CI 0.34–0.37).

Discussion

We find substantial excess all-cause mortality that exceeds the number of documented COVID-19 deaths in most of the 13 states evaluated: California, Colorado, Connecticut, Illinois, Louisiana, Massachusetts, Michigan, New Jersey, New York and Pennsylvania. Up until 9 May, we estimate over 100 000 excess deaths in the U.S. due to the COVID-19 pandemic. Mortality underestimation may reduce the public's willingness to adhere to costly and stressful non-pharmaceutical interventions, such as governors' orders to stay at home, wear masks and engage in social distancing.




Fig. 4. Weekly influenza mortality grouped by year and state starting on week 40 of 2015 until 9 May 2020.




Fig. 5. Weekly mortality in the United States by year starting on week 40 of 2015 until 9 May 2020.

Mechanisms for excess mortality

The CDC has established guidelines for certifying COVID-19 deaths [21] and whether to collect postmortem specimens for SARS-CoV-2 testing [22]. We propose the following potential mechanisms for underestimation of pandemic death toll: underdiagnosis of COVID-19 due to low availability of SARS-CoV-2 tests; indirect deaths from not seeking care for emergent non-COVID-19 conditions; not seeking care for what appeared to be non-severe COVID-19 and then experiencing sudden declines characteristic of COVID-19; or needing treatment for COVID-19 or other ailments and being turned away from

emergency departments due to crowding, and subjective interpretations of guidelines. COVID-19 test access has been quantified as the percent of SARS-CoV-2 polymerase chain reaction (PCR) tests that are positive; the percent of PCR tests that are positive decreased during this period, suggesting increased test access [23]. However, substantial heterogeneity in test availability across states [13] means that excess mortality may not decrease substantially unless test availability increases in high-prevalence states.

Some excess mortality may include indirect deaths from emergent non-COVID-19 conditions due to delaying healthcare, due to fear of becoming infected with SARS-CoV-2 during the

Table 1. Excess all-cause, pneumonia and influenza mortality 95% confidence intervals from 2 models, from states with the largest reported COVID-19 mortality data as of 9 May 2020, and with official COVID-19 toll

Jurisdiction	Start date	COVID-19 Deaths	All-cause excess deaths		Pneumonia excess deaths		Influenza excess deaths	
			Semiparametric	Conventional	Semiparametric	Conventional	Semiparametric	Conventional
California	21 March 2020	2849	(3338, 6344)	(3638, 9058)	(1729, 2370)	(1969, 2900)	(-75, 52)	(120, 359)
Colorado	21 March 2020	1130	(1175, 1730)	(960, 1882)	(620, 803)	(557, 807)	(-26, 15)	(-61, 36)
Connecticut	21 March 2020	2932	(3095, 3952)	(3092, 4008)	(651, 844)	(638, 864)	(-20, 5)	(-63, 18)
Florida	28 March 2020	1840	(1271, 2856)	(392, 3934)	(1100, 1439)	(1373, 1966)	(-39, 21)	(-200, 7)
Illinois	21 March 2020	3525	(4646, 6111)	(5111, 7357)	(1974, 2422)	(2088, 2566)	(-20, 44)	(8, 129)
Indiana	28 March 2020	1490	(1400, 2078)	(1198, 2613)	(679, 882)	(588, 941)	(-28, 14)	(-60, 66)
Louisiana	21 March 2020	2267	(2341, 3183)	(2522, 3834)	(1042, 1263)	(970, 1288)	(-3, 27)	(14, 68)
Massachusetts	28 March 2020	5050	(5562, 7201)	(5516, 7152)	(2044, 2456)	(2012, 2439)	(-100, 39)	(-111, 34)
Michigan	21 March 2020	5036	(5581, 7171)	(5514, 7474)	(2386, 2926)	(2458, 2910)	(-52, 28)	(-36, 138)
New Jersey	21 March 2020	10465	(13 170, 16 058)	(13 834, 15 567)	(5550, 6539)	(5879, 6375)	(2, 46)	(-46, 61)
New York	21 March 2020	26584	(32 538, 39 960)	(35 632, 38 802)	(12 016, 14 310)	(12 860, 13 623)	(694, 911)	(640, 930)
Pennsylvania	21 March 2020	3793	(5125, 6560)	(4653, 6809)	(1757, 2135)	(1686, 2135)	(-65, -8)	(-96, 90)
Washington	29 February 2020	925	(559, 1633)	(421, 1796)	(358, 623)	(359, 674)	(-3,72)	(-20, 78)
United States	21 March 2020	73834	(100 013, 127 501)	(106 940, 143 478)	(40 066, 47 391)	(41 613, 47 841)	(15, 1385)	(-33, 2896)

All data used included mortality until 9 May 2020 included in the 4 September 2020 data release.

The semiparametric method uses a starting date, but the conventional method does not.

The table presents prediction intervals using the conventional method, although we refer to confidence intervals throughout for consistency.

COVID-19 pandemic. Other research suggests that patients with heart attacks and stroke delayed seeking care due to the COVID-19 pandemic [24]. Our research suggests some deaths could include deaths from chronic lower respiratory diseases, such as deaths due to not seeking care for asthma syndrome. In this research study, we were not able to access emergency department visit data for acute coronary syndromes, only asthma syndrome ED visits in NYC. When the complete 2020 mortality data are released, we would expect more deaths at home coded as chronic lower respiratory diseases, cardiovascular disease and cerebrovascular diseases than usual; normally, these are three of the top five causes of death in the US, so reduced care-seeking could contribute substantially to excess mortality [25].

Patients who suspect COVID-19 may not seek healthcare or may be turned away from emergency departments: these patients would not have SARS CoV-2 test results, so they would not be coded as COVID-19 deaths. Many patients with influenza-like illness (ILI) never seek healthcare, including patients likely to have severe effects: about 45% of patients with heart disease and 52% with COPD delay at least 3 days [26], and during a flu pandemic care-seeking increases by only about 10 percentage points [4]. Dyspnoea/breathlessness predicts healthcare seeking for ILIs [27]. However, most severe or fatal COVID-19 cases do not present with dyspnoea [28], and lung damage can be substantial even without dyspnoea [29]. Sudden health declines have been observed in COVID-19 inpatient populations: patients decline in minutes from ambulatory/conversant to unresponsive and requiring resuscitation [30], and such sudden health declines could also occur in outpatient populations.

Some but not all of the excess COVID-19 mortality is captured by pneumonia excess mortality, but some sudden deaths seem to occur among patients without apparent pneumonia [31]. These deaths may be due to cardiac injury [32], kidney or liver injury [33], or hypercoagulability [34]. Further, our results suggest that excess deaths for cardiovascular, cerebrovascular, kidney or liver failure without coding for COVID-19 may be apparent when these data become available.

Advantages of the semiparametric model

The CDC estimates and publishes excess mortality counts during the COVID-19 pandemic, but without quantifying uncertainty like our methods do. It can be shown that under a mixed model representation, the semiparametric model estimates are the best linear unbiased predictors [35]. Moreover, the intervals from our two methods always overlap. Yet the semiparametric method yields more precise confidence intervals than a conventional approach, which must estimate prediction intervals. Prediction intervals are wider than confidence intervals because they account for uncertainty in post-pandemic deaths. That is, for week 19 of 2020, the conventional model estimates excess deaths as the difference between the observed deaths, and what pre-pandemic projected forward model expects the number of deaths to be. Those observed deaths in week 19 are subject to random variation in mortality which the interval must account for. In contrast, the semiparametric model estimates excess deaths as the difference of two expected values: expected mortality with a pandemic period indicator and expected mortality without a pandemic period indicator. Intervals of parameters are always narrower than for random variables. Wider intervals hinder interpretation of excess deaths, so we focus on the results from the semiparametric model. The semiparametric model is also less

affected by under-reporting during the pre-pandemic period than the conventional approach.

Misclassification of excess deaths

We quantify higher pneumonia mortality than expected in all 13 states and higher influenza deaths primarily in New York. For New Jersey, even when adjusting for COVID-19 official deaths, pneumonia and influenza mortality, excess deaths are still significant, which raises two potential explanations: COVID-19 deaths may have been misclassified or New Jersey may have had more indirect deaths than other states. With only limited cause of death data, our analysis is unable to distinguish between misclassified COVID-19 deaths and indirect deaths.

Many excess influenza deaths in New York City appear to be misclassified COVID-19 deaths. If NYC's COVID-19 emergency declaration led people with seasonal influenza not to seek care, we would expect to see a sharp reduction in the number of positive influenza cases around the date of the emergency declaration. However, the number of positive influenza tests in New York City decreased steadily throughout March 2020 with no steep drop around the date of the COVID-19 emergency declaration [36]. Because seasonal influenza seemed to taper off during March 2020, while influenza deaths in NYC increased until April 11th. This suggests that many excess influenza deaths were misclassified COVID-19 deaths, rather than a resurgence of undiagnosed influenza. The apparent misclassification of COVID-19 deaths as influenza in New York City does not appear attributable to urbanicity because we observed no excess influenza mortality in the District of Columbia, the other urban-only area. The likely misclassification of COVID-19 deaths as influenza may be due to heterogeneity in cause of death determination and/or COVID-19 presentations between New York City and the states examined. Alternatively, the misclassification may occur in many jurisdictions, but it is more detectable in NYC due to the large number of deaths.

Mortality displacement hypothesis

Excess mortality during heatwaves and influenza pandemics often shows mortality displacement (or harvesting effect), where subsequent mortality declines [37]. Longer observation periods could detect mortality displacement, but inconsistent non-pharmaceutical intervention policies across the United States may cause elevated mortality due to COVID-19 to persist over longer durations than during typical influenza pandemics.

Strengths and limitations

Our hypothesised mechanisms for excess mortality are based on existing research, but the available mortality data are insufficient to test these hypotheses. For example, deaths at home are not published weekly or systematically. The available U.S. data include data aggregated over all states stratified by age (0–17, 18–64, 65+) and region; however, these data do not allow identification of all-cause mortality trends by region or age because some states' data are incomplete, even by the available completeness measure, which understates completeness during periods of elevated mortality.

Our analysis examines excess deaths associated with the COVID-19 pandemic. It is likely that the longer the period since the beginning of the pandemic, the more indirect causes

of death are included in our excess deaths estimate. The vast majority of excess mortality is not attributable to social distancing or the pandemic-induced recession because recessions are generally associated with lower mortality [38]. Furthermore, the statistical methods used can estimate excess mortality in regions with considerable increases in fatalities. In regions with very small number of increased deaths, our methods may not be able to detect the effects of the pandemic because the confidence intervals would be too wide.

We can evaluate whether emergency department visits for asthma in New York City decreased during the COVID-19 pandemic but not whether the decrease in asthma ED visits increased mortality because chronic lower respiratory mortality data from this period are not currently available. We were unable to obtain data from the other 58 NSSP jurisdictions, or for acute coronary syndromes that could suggest stroke or heart attack.

Implications for policy and practice

Research can identify populations at risk for mortality that may not be included in the official COVID-19 counts, and the overlap with groups affected by other health disparities, so resources can be allocated to the most affected communities. Excess mortality may be reduced by prioritising research, including random sample testing of people without symptoms and postmortem tests [39]. To avoid ascertainment bias, random sample postmortem testing can identify atypical disease presentations that may be under-recognised in clinical settings. In the face of testing limitations, postmortem tests may be viewed as expendable, but postmortem testing can improve patient care by identifying gaps in diagnosis and treatment.

To identify under-use of healthcare for cardiovascular and cerebrovascular conditions, National Surveillance System Program data should include these indications and current data should be available for all NSSP locations. New York City's system suggests that this change to make data more quickly available is feasible. NSSP jurisdictions are given substantial discretion over which syndromes are included and may consider centralised standards impractical, but such standards would make data useful nationwide, in addition to locally.

Future federal pandemic planning should include upgrades to state vital statistics infrastructure, so that all states can report deaths in a timely fashion. As suggested after earlier pandemics [40], pandemic planning should identify how to release more detailed data so that research can discriminate between mechanisms of excess mortality, especially for high-vulnerability jurisdictions. Research using detailed data will find some spurious findings, including cases who died with the virus but not of the virus, but more detailed data will save lives by identifying vulnerable communities to allocate resources to, as well as atypical symptoms of the disease.

Conclusions

Excess all-cause mortality exceeding the number of reported COVID-19 deaths is evident in the United States and in many states during the first three months of the pandemic. Greater test availability, including postmortem tests, can yield more accurate mortality counts and case-fatality ratios and increase the public's willingness to adhere to non-pharmaceutical interventions to reduce transmission.

Acknowledgements. We thank Farida Ahmen, Michael Augenbraun, Stephan Kohlhoff, Josh Marshall and Tracey Wilson for helpful conversations, and our spouses/partners for childcare. We also thank the reviewers and editor for their feedback. This research study was partially supported by NSF Grant OAC-1940179.

Conflict of interest. Authors have no conflict of interest to report.

Data availability statement. Data are publicly available but updated weekly. A copy of the data release is shared through GitHub.

References

1. **Ricardo Ribas Freitas A, Rita Donalisio M and Mar'ia Alarc'on-Elbal P** (2018) Excess mortality and causes associated with chikungunya, Puerto Rico, 2014–2015. *Emerging Infectious Diseases* **24**, 2352.
2. **Rivera R and Rolke W** (2019) Modeling excess deaths after a natural disaster with application to Hurricane Maria. *Statistics in Medicine* **38**, 4545–4554.
3. **Krantz SG and Srinivasa Rao ASR** (2020) Level of underreporting including underdiagnosis before the first peak of COVID-19 in various countries: preliminary retrospective results based on wavelets and deterministic modeling. *Infection Control and Hospital Epidemiology* **41**, 857–861.
4. **Ma W, Huo X and Zhou M** (2018) The healthcare seeking rate of individuals with influenza like illness: a metaanalysis. *Infectious Diseases*, 50:728–735.
5. **Simonsen L et al.** (2013) Global mortality estimates for the 2009 influenza pandemic from the glamor project: a modeling study. *PLoS Medicine* **10**, 1–17.
6. **Parpia AS et al.** (2016) Effects of response to 2014–2015 Ebola outbreak on deaths from malaria, HIV/AIDS, and tuberculosis, West Africa. *Emerging Infectious Diseases* **22**, 433.
7. **Shah SM et al.** (2013) The effect of unexpected bereavement on mortality in older couples. *American Journal of Public Health* **103**, 1140–1145.
8. **Hoot NR and Aronsky D** (2008) Systematic review of emergency department crowding: causes, effects, and solutions. *Annals of Emergency Medicine* **52**, 126–136.e1.
9. **Richardson S et al.** (2020) Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. *JAMA* **323**, 2052–2059.
10. **Woolhandler S, Himmelstein DU and Intersecting US** (2020) Epidemics: COVID-19 and lack of health insurance. *Annals of Internal Medicine* **173**, 63–64.
11. **Spencer MR and Ahmad F** (2016) Timeliness of death certificate data for mortality surveillance and provisional estimates. Vital statistics rapid release special report no. 001. US Department of Health and Human Services, Centers for Disease Control and Prevention. National Center for Health Statistics, National Vital Statistics System. Available at <https://www.cdc.gov/nchs/data/vsrr/report001.pdf>.
12. **US Census Bureau.** National population by characteristics: 2010–2019. Available at <https://www.census.gov/data/tables/time-series/demo/popest/2010snational-detail.html>.
13. **Madrigal A, Hammerbacher J, Kissane E and COVID Tracker team.** COVID tracking project. Available at <https://covidtracking.com/data>.
14. **New York Times** (2020) Coronavirus in the U.S.: latest map and case count. Available at <https://www.nytimes.com/interactive/2020/us/coronavirus-uscases.html>.
15. **CDC** (2020) Daily updates of totals by week and state: provisional death counts for coronavirus disease 2019 (COVID-19). Available at <https://www.cdc.gov/nchs/nvss/vsrr/COVID19/index.htm>.
16. **Santos-Burgoa C et al.** (2018) Differential and persistent risk of excess mortality from Hurricane Maria in Puerto Rico: a time-series analysis. *The Lancet Planetary Health* **2**, e478–e488.
17. **Ver Hoef JM and Boveng PL** (2007) Quasi-Poisson vs. negative binomial regression: how should we model overdispersed count data? *Ecology* **88**, 2766–2772.

18. **Quealy K** (2020) The upshot: the richest neighborhoods emptied out most as coronavirus hit New York City [original data analysis]. *New York Times*. May 15, 2020.
19. **Wood SN** (2017) *Generalized Additive Models: An introduction with R*. United States: Chapman & Hall/CRC.
20. **R Core Team** (2016) *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing.
21. **National Vital Statistics System** (2020) Guidance for certifying deaths due to coronavirus disease 2019 (COVID-19). National Vital Statistics System: vital statistics reporting guidance (Report 3), April 2020.
22. **CDC** (2020) Coronavirus disease 2019 (COVID-19): collection and submission of postmortem specimens from deceased persons with known or suspected COVID-19, March 2020 (interim guidance). Available at <https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-postmortemspecimens.html>.
23. **CDC** (2020) COVIDView: a weekly surveillance summary of U.S. COVID-19 activity. Available at <https://www.cdc.gov/coronavirus/2019-ncov/coviddata/covidview/index.html>.
24. **Boukhris M et al.** (2020) Cardiovascular implications of the Covid-19 pandemic: a global perspective. *Canadian Journal of Cardiology* **S0828282X:30464–5**.
25. **CDC** (2020) Leading causes of death: data are for the U.S. Available at <https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm>.
26. **Biggerstaff M et al.** (2014) Influenza-like illness, the time to seek healthcare, and influenza antiviral receipt during the 2010–2011 influenza season – United States. *The Journal of Infectious Diseases* **210**, 535–544.
27. **Parshall MB et al.** (2012) An official American thoracic society statement: update on the mechanisms, assessment, and management of dyspnea. *American Journal of Respiratory and Critical Care Medicine* **185**, 435–452.
28. **Li R et al.** (2020) Clinical characteristics of 225 patients with COVID-19 in a tertiary Hospital near Wuhan, China. *Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology* **127**, 104363.
29. **Li L-Q et al.** (2020) COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. *Journal of Medical Virology* **127**, 1–3.
30. **Lescure F-X et al.** (2020) Clinical and virological data of the first cases of COVID-19 in Europe: a case series. *The Lancet Infectious Diseases* **92**, 577–583.
31. **Lin L et al.** (2020) Hypothesis for potential pathogenesis of SARS-CoV-2 infection – a review of immune changes in patients with viral pneumonia. *Emerging Microbes & Infections* **9**, 727–732.
32. **Guo T et al.** (2020) Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). *JAMA Cardiology* **5**, 811–818.
33. **Cheng Y et al.** (2020) Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney International* **97**, 829–838.
34. **Terpos E et al.** (2020) Hematological findings and complications of COVID-19. *American Journal of Hematology* **95**, 834–847.
35. **Ruppert D, Wand MP and Carroll RJ** (2003) *Semiparametric Regression*. Cambridge: Cambridge University Press.
36. **New York City Department of Health and Mental Hygiene** (2020) Influenza surveillance report week ending April 18, 2020 (Week 16).
37. **Lytras T et al.** (2019) Mortality attributable to seasonal influenza in Greece, 2013 to 2017: variation by type/subtype and age, and a possible harvesting effect. *Euro Surveillance: Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin* **24**, 1–10.
38. **Margerison-Zilkko C et al.** (2016) Health impacts of the great recession: a critical review. *Current Epidemiology Reports* **3**, 81–91.
39. **Lipsitch M, Swerdlow DL and Finelli L** (2020) Defining the epidemiology of Covid-19 – studies needed. *New England Journal of Medicine* **382**, 1194–1196.
40. **Prieto DM, et al.** (2012) A systematic review to identify areas of enhancements of pandemic simulation models for operational use at provincial and local levels. *BMC Public Health* **12**, 251.

Appendix

Detailed methods

Semiparametric excess mortality model

Covariates include week of the year, year, an indicator function that presents the possibility that the mean death rate has increased after the start of the emergency in a location, and the natural logarithm of population as an offset. Week of the year is modelled non-parametrically to capture seasonal mortality variations. Let D_t = number of certified deaths at time index t , N_t = population size. We use p_t as an indicator of time period t falls in. The indicator variable permits us to estimate excess deaths. Specifically, $p_t = 0$ represents the pre-emergency period; $p_t = 1$, the period after the emergency. Moreover, let $week_t$ = week of year, and $year_t$ = a categorical year effect.

Assuming D_t follows a Poisson distribution, we fit a semiparametric model;

$$\log(\mu_t) = \log(N_t) + \beta_0 + \beta_1 p_t + f(\text{week}_t) + \text{year}_t \quad (\text{A1})$$

where $\mu_t = E(D_t | t, p_t, N_t, \text{week}_t, \text{year}_t)$. The natural logarithm of N_t is an offset variable; while f is a smooth function of $week$, which accounts for within year variation. f is fit using a penalised cyclic cubic regression spline [19].

Preliminary analysis indicates overdispersion, so we used a quasi-Poisson model to estimate the dispersion parameter [17]. We estimated coefficients by a penalised likelihood maximisation approach, where the smoothing penalty parameters are determined by restricted maximum likelihood. The residuals of the fitted model (1) did not present remaining temporal dependence.

The fit of model (A1) can be used to estimate excess deaths through the difference between the estimated model with $p_t = 1$, vs. the estimated model with $p_t = 0$. Let $\hat{\mu}_t = E(D_t | t, p_t = 1, N_t, \text{week}_t, \text{year}_t)$, $\hat{\psi}_t = E(D_t | t, p_t = 0, N_t, \text{week}_t, \text{year}_t)$, and \hat{b}_0, \hat{b}_1 estimate β_0, β_1 respectively. Then [2],

$$\hat{\mu} - \hat{\psi}_t = e^{\hat{b}_0 + \hat{f}(\text{week}_t) + \text{year}_t} (e^{\log(N_t)\hat{b}_1} - 1) \quad (\text{A2})$$

When $p_t = 0$, then $\hat{\mu}_t - \hat{\psi}_t = 0$. Equation (A2) is the maximum likelihood estimator for expected excess deaths at t .

To estimate cumulative excess deaths we use (A2)

$$\sum_{t=q}^r (\hat{\mu}_t - \hat{\psi}_t) \quad (\text{A3})$$

for any time period starting at index q and ending at r . Approximate simulations from the Bayesian posterior density are performed to obtain 95% credibility intervals, which we refer to as confidence intervals throughout.

Conventional mortality method

Conventional excess mortality methods build a temporal mortality model until time $m < T$, then use this model to predict deaths from time $m + 1$ to time T , and excess deaths are the difference between the deaths between times $m + 1$ and T and the predicted deaths from the model. Uncertainty is usually quantified through the uncertainty of the parameters on the regression model [16], which ignores natural random fluctuations in mortality from time $m + 1$ to time T . We tackle this problem combining the Bayesian posterior density described in the semiparametric model section with uncertainty on weekly mortality.

First, we fit a quasi-Poisson semiparametric model similar to the one presented in the previous section, but here we only use data until 1 February 2020. The deaths from 8 February 2020 forward should follow a Poisson distribution with some expected rate; the maximum likelihood estimator of such rate is the mean weekly deaths during this period. The weekly deaths are approximately normal with a variance that accounts for overdispersion according to the scale parameter in the fitted model. From this distribution, we simulate 10 000 weekly deaths and subtract the results from the posterior distributions of the fitted results. The 95% confidence interval is the range between the 2.5% and 97.5% percentiles of all excess deaths.